Inici › Mieloma múltiple › Nebraska › Omaha
Assaigs clínics de Mieloma múltiple a Omaha, NE
16 estudis de Mieloma múltiple busquen participants en centres de Omaha i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 3
- Nebraska Cancer Specialists, Omaha
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
ReclutantFase 3
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ReclutantFase 2
- University of Nebraska Medical Center, Omaha
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
ReclutantFase 1/2
- Nebraska Cancer Institute, Omaha
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
Reclutant
- University of Nebraska Medical Center, Omaha
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
ReclutantFase 3
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
ReclutantFase 1
- University of Nebraska, Omaha
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
ReclutantFase 2
- University of Nebraska Medical Center, Omaha
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy
Reclutant
- Unversity of Nebraska Medical Center, Omaha
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
ReclutantFase 1
- University Of Nebraska Medical Center, Omaha
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 1
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 282497, Omaha
Halt Aging in Survivors of Blood Cancers
Reclutant
- University of Nebraska Medical Center, Omaha
Integrated Cancer Repository for Cancer Research
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Methodist Estabrook Cancer Center, Omaha
- Nebraska Methodist Health System, Omaha
- University of Nebraska Medical Center, Omaha
- i 1 més
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
ReclutantFase 1/2
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
ReclutantFase 3
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
- i 1 més
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
ReclutantFase 2
- Nebraska Cancer Specialists, Omaha
Assaigs de Mieloma múltiple en altres ciutats
- New York City, NY60 estudis
- Boston, MA42 estudis
- Atlanta, GA41 estudis
- Houston, TX38 estudis
- Durham, NC37 estudis
- Nashville, TN32 estudis
- Denver, CO27 estudis
- Rochester, MN24 estudis
- St. Louis, MO24 estudis
- Columbus, OH24 estudis
- Baldwin Park, CA23 estudis
- Chicago, IL22 estudis
Altres estudis a Omaha
- Càncer de pròstata27 estudis
- Càncer de pulmó de cèl·lules no petites24 estudis
- Càncer de mama22 estudis
- Càncer colorrectal18 estudis
- Càncer (tots els tipus)18 estudis
- Limfoma no Hodgkin14 estudis
- Càncer d'ovari14 estudis
- Càncer de pàncrees14 estudis
- Carcinoma de cèl·lules escamoses de cap i coll13 estudis
- Insuficiència cardíaca13 estudis
- Càncer metastàtic13 estudis
- Càncer de ronyó (carcinoma de cèl·lules renals)12 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.